山东步长制药股份有限公司关于注销回购股份的实施公告

Core Viewpoint - The company will cancel 51,474,203 repurchased shares, accounting for 4.65% of the total shares before cancellation, reducing the total share capital from 1,106,042,645 shares to 1,054,568,442 shares after the cancellation [2][7]. Group 1: Share Repurchase and Cancellation Details - The company approved a share repurchase plan on December 13, 2023, with a total fund of no less than 180 million yuan and no more than 360 million yuan, with a maximum repurchase price of 24 yuan per share [3]. - The repurchase amount was later increased to between 360 million yuan and 720 million yuan, with the company completing the repurchase by November 6, 2024, acquiring 44,853,573 shares at an average price between 14.16 yuan and 17.44 yuan, totaling approximately 712.38 million yuan [3][4]. - A second repurchase plan was approved on December 26, 2024, with a total fund of no less than 50 million yuan and no more than 100 million yuan, with a maximum price of 23 yuan per share, resulting in the acquisition of 6,620,630 shares by May 9, 2025, at prices between 13.86 yuan and 15.07 yuan, totaling approximately 98.06 million yuan [4]. Group 2: Approval and Legal Compliance - The cancellation of repurchased shares was approved in meetings held on April 25 and May 26, 2025, with the purpose of reducing registered capital [5]. - The company will follow relevant laws and regulations for the cancellation process, with the cancellation expected to be completed on August 12, 2025 [7]. - The company has notified creditors regarding the cancellation, and no requests for early debt repayment or guarantees were received within the stipulated period [7].